Mizuho lowered the firm’s price target on EyePoint (EYPT) to $26 from $30 and keeps an Outperform rating on the shares following the Q1 report. The firm’s focus remains on the clinical progress with lead asset Duravyu but it updated the company’s model to reflect higher than expected expenses
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint reports inducement grants under NASDAQ listing rule
- Positive Buy Rating for EyePoint Pharmaceuticals Driven by Clinical Progress and Strong Financial Position
- EyePoint Pharma’s Promising Q1 2025 Financial Results
- EyePoint Pharma’s Earnings Call Highlights Positive Momentum
- EyePoint Pharmaceuticals: Strong Buy Rating Backed by Promising Clinical Trial Progress and Market Potential